Medivir
1.44
SEK
+2.13 %
Less than 1K followers
MVIR
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
+2.13%
-38.72%
-49.3%
-44.83%
-49.3%
-47.44%
-78.22%
-85.59%
-97.54%
Medivir is a pharmaceutical company focused on developing innovative treatments for cancer and infectious diseases. The company is researching new therapies that can improve patient outcomes and quality of life. The company operates globally with a primary presence in Europe and North America. Medivir was founded in 1991 and is headquartered in Stockholm, Sweden.
Read moreMarket cap
165.05M SEK
Turnover
4.1K SEK
Revenue
3.5M
EBIT %
-3,637.14 %
P/E
-
Dividend yield-%
-
Financial calendar
29.4
2025
Interim report Q1'25
7.5
2025
General meeting '25
21.8
2025
Interim report Q2'25
ShowingAll content types
Medivir’s partner Infex Therapeutics signs a license agreement for the clinical development of MET-X in India
BioStock: Medivir's investigator on the positive results directly from EASL
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Carnegie Access: Medivir: Final study results presented at EASL
Medivir presents positive final phase 1b/2a fostrox + Lenvima data in advanced liver cancer at EASL Liver Cancer Summit
Carnegie Access: Medivir: Financing uncertainty still tops the agenda – Q4(24) review
Redeye: Medivir Q4 2024 - Phase IIb Trial Design Set
Medivir's CEO: "We have attracted interest from the best investigators and hospitals to be part of the phase IIb study"
